PHAT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

Oct 29, 2026

8-K

Phathom Pharmaceuticals Announces FDA Public Docket Establishment Regarding VOQUEZNA NCE Exclusivity and Related Litigation

Oct 26, 2026

8-K

Phathom Pharmaceuticals Announces BDR Lawsuit Against FDA Over VOQUEZNA Exclusivity

Oct 23, 2026

8-K

Phathom Pharmaceuticals Initiates Patient Screening in Phase 3 Study of VOQUEZNA for Non-Erosive GERD

Sep 29, 2026

8-K

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 30, 2026

8-K

Phathom Pharmaceuticals Completes Enrollment in Phase 2 Study of VOQUEZNA for Eosinophilic Esophagitis

Jun 23, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jan 8, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Guggenheim Securities, Cantor

Jan 7, 2026

424B5

8,695,652 Shares of Common Stock

Aug 19, 2024

424B5

11,125,000 Shares

May 24, 2023

424B5

Common Stock

May 23, 2023

424B5

5,000,000 Shares-

Oct 26, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 27, 2026

S-3ASR

SHARE RESALE REGISTRATION

Jan 7, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 6, 2025

FWP

Common Stock

Aug 19, 2024

S-3

SHELF | ATM | Offering amount: $500,000,000.00 EFFECTIVE

Nov 9, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 12, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 12, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

Frazier Life Sciences Public Fund, L.P. (Filed by)

Nov 2, 2026

Narula Sanjeev (Reporting)

Oct 8, 2026

Breedlove Robert Charles (Reporting)

Sep 8, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Jul 29, 2026

SCHEDULE 13G/A

MILLENNIUM MANAGEMENT LLC (Filed by)

Jul 20, 2026

Breedlove Robert Charles (Reporting)

Jul 16, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jun 25, 2024

CORRESP

Form CORRESP - Correspondence

Jun 14, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jun 6, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 20, 2023

CORRESP

Form CORRESP - Correspondence

Nov 15, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 15, 2023

Phathom Pharmaceuticals, Inc. PHAT · SEC Filings